This is a 16-week, Single-center, Randomized, Open Label, Parallel Controlled Group
Comparison of the Comprehensive Glycemic Control of Exenatide and Insulin Glargine on Type 2
Diabetes Patients Inadequately Controlled With Metformin Monotherapy.
Phase:
Phase 4
Details
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School